This Guideline has been developed by the appropriate ICH Expert Working Group and has been subject to consultation by the regulatory parties, in accordance with the ICH Process. At Step 4 of the Process the final draft is recommended for adoption to the regulatory bodies of the European Union, Japan and USA.
Q4B Annex 4C(R1)
Document History

<table>
<thead>
<tr>
<th>Code</th>
<th>History</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q4B Annex 4C</td>
<td>Approval by the Steering Committee under Step 2 and release for public consultation.</td>
<td>5 June 2008</td>
</tr>
<tr>
<td>Q4B Annex 4C</td>
<td>Approval by the Steering Committee under Step 4 and recommendation for adoption to the three ICH regulatory bodies.</td>
<td>12 November 2008</td>
</tr>
</tbody>
</table>

Current Step 4 version

<table>
<thead>
<tr>
<th>Code</th>
<th>History</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q4B Annex 4C(R1)</td>
<td>Integration of the Health Canada Interchangeability Statement under Section 4.5 after approval by the Steering Committee.</td>
<td>27 September 2010</td>
</tr>
</tbody>
</table>
EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL TEXTS FOR USE IN THE ICH REGIONS

ON

MICROBIOLOGICAL EXAMINATION OF NON-STERILE PRODUCTS:
ACCEPTANCE CRITERIA FOR PHARMACEUTICAL PREPARATIONS AND SUBSTANCES FOR PHARMACEUTICAL USE

GENERAL CHAPTER

ICH Harmonised Tripartite Guideline

Having reached Step 4 of the ICH Process at the ICH Steering Committee meeting on 12 November 2008, this guideline is recommended for adoption to the three regulatory parties to ICH

(This annex was revised -R1- to include the Interchangeability Statement from Health Canada on September 27, 2010)

TABLE OF CONTENTS

1. INTRODUCTION .......................................................................................................... 1

2. Q4B OUTCOME ............................................................................................................. 1

3. TIMING OF ANNEX IMPLEMENTATION ..................................................................... 1

4. CONSIDERATIONS FOR IMPLEMENTATION ............................................................ 1

  4.1 General Consideration ........................................................................................... 1

  4.2 FDA Consideration .............................................................................................. 2

  4.3 EU Consideration .................................................................................................. 2

  4.4 MHLW Consideration .......................................................................................... 2

  4.5 Health Canada Consideration .............................................................................. 2

5. REFERENCES USED FOR THE Q4B EVALUATION .............................................. 2
EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL TEXTS FOR USE IN THE ICH REGIONS

ON

MICROBIOLOGICAL EXAMINATION OF NON-Sterile PRODUCTS: ACCEPTANCE CRITERIA FOR PHARMACEUTICAL PREPARATIONS AND SUBSTANCES FOR PHARMACEUTICAL USE

GENERAL CHAPTER

1. INTRODUCTION

This annex is the result of the Q4B process for Microbiological Examination of Non-Sterile Products: Acceptance Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical Use.

For each regulatory region, the pharmacopoeial text is non-mandatory and is provided for informational purposes only.

The proposed texts were submitted by the Pharmacopoeial Discussion Group (PDG).

2. Q4B OUTCOME

The ICH Steering Committee, based on the evaluation by the Q4B Expert Working Group (EWG), recommends that the official pharmacopoeial texts, Ph.Eur. 5.1.4. Microbiological Quality of Non-Sterile Pharmaceutical Preparations and Substances for Pharmaceutical Use, JP General Information 12. Microbial Attributes of Non-sterile Pharmaceutical Products, and USP <1111> Microbiological Attributes of Nonsterile Pharmaceutical Products, can be used as interchangeable in the ICH regions.

3. TIMING OF ANNEX IMPLEMENTATION

When this annex is implemented (incorporated into the regulatory process at ICH Step 5) in a region, it can be used in that region. Timing might differ for each region.

4. CONSIDERATIONS FOR IMPLEMENTATION

4.1 General Consideration

When sponsors or manufacturers change their existing methods to the implemented Q4B-evaluated pharmacopoeial texts that are referenced in Section 2 of this annex, any change notification, variation, and/or prior approval procedures should be handled in accordance with established regional regulatory mechanisms pertaining to compendial changes.

4.2 FDA Consideration

Based on the recommendation above, and with reference to the conditions set forth in this annex, the pharmacopoeial texts referenced in Section 2 of this annex can be considered interchangeable. However, FDA might request that a company demonstrate that the chosen method is acceptable and suitable for a specific material or product, irrespective of the origin of the method.
4.3 EU Consideration
For the European Union, the monographs of the Ph. Eur. have mandatory applicability. Regulatory authorities can accept the reference in a marketing authorisation application, renewal or variation application citing the use of the corresponding text from another pharmacopoeia as referenced in Section 2, in accordance with the conditions set out in this annex, as fulfilling the requirements for compliance with the Ph. Eur. Chapter 5.1.4. on the basis of the declaration of interchangeability made above.

4.4 MHLW Consideration
The pharmacopoeial texts referenced in Section 2 of this annex can be used as interchangeable in accordance with the conditions set out in this annex. Details of implementation requirements will be provided in the notification by MHLW when this annex is implemented.

4.5 Health Canada Consideration
In Canada, any of the texts cited in section 2 of this annex and used in accordance with the conditions set out in this annex can be considered interchangeable.

5. REFERENCES USED FOR THE Q4B EVALUATION

5.2 The pharmacopoeial references for Microbiological Examination of Non-Sterile Products: Acceptance Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical Use for this annex are:

5.2.1 European Pharmacopoeia (Ph. Eur.): 6.3 Edition (official on January 2009) Microbiological Quality of Non-Sterile Pharmaceutical Preparations and Substances for Pharmaceutical Use (reference 01/2009: 50104); 
